High-dose, short-term corticosteroids for ARDS caused by COVID-19: a case series.
Clara SoShosei RoManabu MurakamiRyosuke ImaiTorahiko JintaPublished in: Respirology case reports (2020)
We report a case series of seven mechanically ventilated patients with acute respiratory distress syndrome (ARDS) caused by coronavirus disease (COVID-19) who received early treatment with high-dose, short-term systemic corticosteroids to prevent cytokine overproduction. Of the seven patients, four were male and median age was 69 years. They were intubated within seven days after admission when their respiratory status rapidly worsened. At that time, we administered 1000 or 500 mg/day for three days of methylprednisolone intravenously, followed by 1 mg/kg and tapered off. The median duration for the total administration of corticosteroids was 13 days. This high-dose, short-term corticosteroid therapy enabled extubation of the patients within seven days. Many questions on the clinical management of COVID-19 remain unanswered, and data on corticosteroid therapy as a choice of treatment are mixed. We present the clinical course of our cases, review the previous evidence, and discuss management.
Keyphrases
- high dose
- acute respiratory distress syndrome
- coronavirus disease
- end stage renal disease
- mechanical ventilation
- extracorporeal membrane oxygenation
- sars cov
- low dose
- chronic kidney disease
- ejection fraction
- stem cell transplantation
- emergency department
- prognostic factors
- peritoneal dialysis
- stem cells
- respiratory syndrome coronavirus
- bone marrow
- mesenchymal stem cells
- cell therapy
- replacement therapy
- deep learning
- patient reported outcomes
- acute kidney injury
- respiratory tract
- data analysis
- smoking cessation